Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors

12. november 2026 oppdatert av: Janssen Research & Development, LLC

A Phase 1 Trial of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors

The purpose of this study is to find out how safe and well-tolerated JNJ-99220732 is and to find out the most suitable dose ([putative] recommended phase 2 dose [pRP2D] regimen[s]) of JNJ-99220732 (Part 1-Dose Escalation). Also, to find out how safe and well-tolerated JNJ-99220732 is at the pRP2D regimen(s) as determined in Part 1 (Part 2- Dose Expansion).

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

200

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion criteria:

- Histological or cytological diagnosis of locally advanced, or metastatic solid tumor, received greater than or equal to (>=) 1 prior line of therapy for recurrent or metastatic disease; progressed or relapsed after or be intolerant to standard therapy approved for the specific tumor type. Participants who actively decline available standard of care therapies are eligible upon documentation of their refusal.

i. Participants with NSCLC must not have known actionable driver alteration for which a targeted therapy is available.

ii. Demonstrated radiographic progression on most recent tumor assessment imaging

  • Participants entering the study must have >=1 measurable lesion as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 that has not been previously irradiated
  • Body weight >=35 kilogram (kg) and body mass index (BMI) >=18 kilogram per square meter (kg/m^2)
  • Eastern cooperative oncology group (ECOG) performance status of 0 or 1
  • Must provide informed consent as described in protocol which includes compliance with the requirements and restrictions listed in the protocol and in the informed consent form (ICF)

Exclusion criteria:

  • Active central nervous system (CNS) involvement with the exception of brain metastases that are clinically stable and asymptomatic for greater than (>)2 weeks off treatment and who are off or receiving low-dose corticosteroid treatment for at least 2 weeks prior to first dose of study treatment
  • Any other malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study treatment, except for squamous and basal cell carcinoma of the skin, non-muscle invasive bladder cancer, or any malignancy considered cured or has minimal risk of recurrence within 1 year of first dose of study treatment
  • Had major surgery within 14 days prior to first dose of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the trial
  • External beam radiation therapy to soft tissue lesions within 14 days prior to start of study treatment
  • History of solid organ or allogeneic hematopoietic stem cell transplant (HSCT)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: JNJ-99220732 (Part 1 and Part 2)

Participants will receive escalating doses of JNJ-99220732 to identify the (putative) recommended phase 2 dose (pRP2D) regimen(s) in Part 1 (dose escalation) of the study. In Part 2 (dose expansion), participants will receive JNJ-99220732 at the pRP2D regimen(s) determined in Part 1 until lost to follow-up, withdrawal of consent, start of subsequent anticancer therapy, completion of the post treatment follow-up or the sponsor decides to stop the trial, whichever occurs first.

JNJ-99220732 will be administered intravenously.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants with Adverse Events (AE) by Severity
Tidsramme: Up to 3 years 2 months

An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An assessment of severity grade will be made by the investigator according to the National cancer institute common terminology criteria for Adverse Events (NCI-CTCAE version 6.0) using the standard grades as follows: Grade 1- Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2- Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL); Grade 3- Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 5- Death related to adverse event.

Up to 3 years 2 months
Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
Tidsramme: Up to 21 days

A DLT is defined as any adverse event that is not clearly due to the underlying disease or extraneous causes that occurs during the DLT period. It includes any toxicity resulting in permanent treatment discontinuation or a delay in dosing of greater than (>)14 days, any Grade 5 toxicity and any death not clearly due to underlying disease or non-study treatment-related cause, high-grade hematological and non-hematological toxicities.

Up to 21 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Serum Concentration Time Profile of JNJ-99220732
Tidsramme: Up to 3 years 2 months

Serum concentrations of JNJ-99220732 over time will be reported.

Up to 3 years 2 months
Maximum Observed Concentration (Cmax) of JNJ-99220732
Tidsramme: Up to 3 years 2 months

Cmax of JNJ-99220732 will be reported.

Up to 3 years 2 months
Trough Concentration (Ctrough) of JNJ-99220732
Tidsramme: Up to 3 years 2 months

Ctrough of JNJ-99220732 will be reported.

Up to 3 years 2 months
Time to Maximum Concentration (Tmax) of JNJ-99220732
Tidsramme: Up to 3 years 2 months

Tmax of JNJ-99220732 will be reported.

Up to 3 years 2 months
Area Under the Concentration-Time Curve from Time Zero to Last Measured Time Point (AUC 0-tau) of JNJ-99220732
Tidsramme: Up to 3 years 2 months

AUC0-tau of JNJ-99220732 will be reported.

Up to 3 years 2 months
Accumulation Ratio of JNJ-99220732
Tidsramme: Up to 3 years 2 months

Accumulation ratio of JNJ-99220732 will be reported.

Up to 3 years 2 months
Number of Participants with Anti-Drug Antibodies Against JNJ-99220732
Tidsramme: Up to 3 years 2 months

Number of participants with anti-drug antibodies against JNJ-99220732 will be reported.

Up to 3 years 2 months
Objective Response Rate
Tidsramme: Up to 3 years 2 months

Objective Response Rate (ORR) is defined as percentage of participants with best objective response of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) criteria.

Up to 3 years 2 months
Disease Control Rate (DCR)
Tidsramme: Up to 3 years 2 months

DCR is defined as the percentage of participants who achieve a confirmed best overall response of CR, PR, or stable disease (SD) based on RECIST version 1.1.

Up to 3 years 2 months
Radiographic Progression-Free Survival (rPFS)
Tidsramme: Up to 3 years 2 months

Radiographic PFS was defined as the time (in months) interval from first dose to the first date of radiographic progression or death. Radiographic progression included progression by bone scan, defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to RECIST v.1.1 criteria).

Up to 3 years 2 months
Duration of Response (DOR)
Tidsramme: Up to 3 years 2 months

DOR is defined as time from date of first documented response (CR/PR) until date of first documented progressive disease (PD) or death, whichever occurs first (according to RECIST v.1.1 criteria).

Up to 3 years 2 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Janssen Research & Development LLC Clinical Trial, Janssen Research & Development, LLC

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

5. januar 2029

Studiet fullført (Antatt)

16. januar 2030

Datoer for studieregistrering

Først innsendt

12. november 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 99220732STM1001
  • 2026-527759-24-00 (Registeridentifikator: EUCT number)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere